Poolbeg Pharma (LSE:POLB) has made a significant step forward in its POLB 001 Phase 2a trial by partnering with Accelerating Clinical Trials Limited to conduct the study and securing a supply of an approved bispecific antibody drug at no cost. The trial, led by Dr. Emma Searle at The Christie NHS Foundation Trust, is designed to evaluate the safety and efficacy of POLB 001 in mitigating Cytokine Release Syndrome in patients with multiple myeloma.
Interim data from the study is expected in 2026, and with a cash runway extending into 2027, Poolbeg is strategically positioned to expand its market potential. The development could transform cancer immunotherapy delivery by making treatments safer and more widely accessible.
Company Overview
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company dedicated to advancing cancer immunotherapies. Its lead candidate, POLB 001, is designed to enable broader administration of cancer therapies—from specialist cancer centers to community hospitals—by preventing the life-threatening side effect of Cytokine Release Syndrome (CRS). In addition, Poolbeg is developing an oral, encapsulated GLP-1 therapy for obesity, targeting large markets and addressing critical unmet medical needs.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply